Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Benatar M, et al. Among authors: wuu j. Neurotherapeutics. 2022 Jul;19(4):1248-1258. doi: 10.1007/s13311-022-01237-4. Epub 2022 May 18. Neurotherapeutics. 2022. PMID: 35585374 Free PMC article. Clinical Trial.
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Benatar M, et al. Among authors: wuu j. Neurotherapeutics. 2022 Sep;19(5):1686. doi: 10.1007/s13311-022-01286-9. Neurotherapeutics. 2022. PMID: 36175782 Free PMC article. No abstract available.
Defining pre-symptomatic amyotrophic lateral sclerosis.
Benatar M, Turner MR, Wuu J. Benatar M, et al. Among authors: wuu j. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):303-309. doi: 10.1080/21678421.2019.1587634. Epub 2019 Mar 20. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 30892087 Free PMC article. Review.
Presymptomatic ALS genetic counseling and testing: Experience and recommendations.
Benatar M, Stanislaw C, Reyes E, Hussain S, Cooley A, Fernandez MC, Dauphin DD, Michon SC, Andersen PM, Wuu J. Benatar M, et al. Among authors: wuu j. Neurology. 2016 Jun 14;86(24):2295-302. doi: 10.1212/WNL.0000000000002773. Epub 2016 May 18. Neurology. 2016. PMID: 27194384 Free PMC article. Review.
Neurofilaments in pre-symptomatic ALS and the impact of genotype.
Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A. Benatar M, et al. Among authors: wuu j. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):538-548. doi: 10.1080/21678421.2019.1646769. Epub 2019 Aug 21. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31432691 Free PMC article.
163 results